We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.825 | 0.80 | 0.85 | 0.85 | 0.80 | 0.80 | 2,269,685 | 10:31:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Drug & Proprietary Stores | 0 | -1.03M | -0.0057 | -1.44 | 1.48M |
From Apr 2019 to Apr 2024
TIDMN4P
RNS Number : 7464Z
N4 Pharma PLC
22 May 2019
22 May 2019
N4 Pharma Plc
("N4 Pharma" or the "Company")
Posting of Annual Report and Notice of AGM
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec(R), a novel delivery system for vaccines and cancer treatments, announces that its Annual Report and Accounts for the year ended 31 December 2018 and Notice of the Annual General Meeting will be posted to shareholders later today, and are available on the Company's website at https://www.n4pharma.com.
The Company's Annual General Meeting will be held at 11.00 a.m. on 19 June 2019 at the offices of Allenby Capital Limited, 5 St Helen's Place, London EC3A 6AB.
For further information please contact:
Enquiries:
N4 Pharma Plc Via Scott PR Nigel Theobald, CEO Allenby Capital Limited Tel: +44(0)203 328 5656 James Reeve/Asha Chotai Scott PR Tel: +44(0)1477 539 539 Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec(R) as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ACSBSGDUCDDBGCB
(END) Dow Jones Newswires
May 22, 2019 02:00 ET (06:00 GMT)
1 Year N4 Pharma Chart |
1 Month N4 Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
